Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).
Derek Alderson(University of Bristol), David Cunningham(Royal Marsden NHS Foundation Trust), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Heike I. Grabsch(University of Leeds), Sally Stenning(Medical Research Council), S M Griffin(Unknown), Cindy Goldstein(MRC Clinical Trials Unit at UCL), Matthew Nankivell(MRC Clinical Trials Unit at UCL), A. Crellin(Leeds Teaching Hospitals NHS Trust), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Alicia Okines(Royal Marsden NHS Foundation Trust), Susan Pritchard, Rupert Langer(Johannes Kepler University of Linz), Joyce Thompson(Heartlands Hospital), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Richard Krysztopik(Royal United Hospital), Stephen Falk(At Bristol)
Cited by 80
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k